COVID-19 mRNA Vaccine: Mechanism and Immune Response

The immune system is divided into two categories: innate immunity, which provides immediate, nonspecific defense through physical barriers (skin, mucous membranes), chemical barriers (lysozyme, gastric acid), and inflammatory responses; and adaptive immunity, which develops a specific, memory-based response to particular antigens through B cells producing antibodies and T cells coordinating the immune attack, offering long-term protection against previously encountered pathogens.

The immune system defends the body against harmful microorganisms and abnormal cells. Antigens are foreign substances that trigger immune responses. Innate immunity provides non-specific defense through anatomical barriers (skin, cilia, flushing), chemical barriers (sweat, mucus, lysozyme, defensins, iron-binding proteins), and biological barriers (normal flora). Interferons are proteins released by infected cells to warn neighboring cells and activate immune cells. Phagocytic cells include macrophages, neutrophils, and natural killer cells. Adaptive immunity provides specific, long-lasting protection. Lymphocytes develop in the thymus (producing T cells) and bone marrow (producing B cells). T cells include helper T cells, cytotoxic T cells, and regulatory T cells. For immune recognition, antigens must be foreign and have large molecular weight. Small molecules called haptens must bind to carrier proteins. Humoral immunity involves B cells producing antibodies, while cell-mediated immunity involves T cells destroying infected or cancer cells through perforin and granzymes.

The immune system protects the body against disease-causing microorganisms. Immunity means protection or resistance against disease. The immune system includes innate immunity (first line of defense present from birth) and adaptive immunity (specific, long-lasting protection). Innate immunity is non-specific and provides general protection against all pathogens. It is transferred from mother to baby through the placenta. Components include physical barriers (skin, mucous membranes), chemical barriers (lysozyme in tears and sweat), and cellular barriers (phagocytic cells like neutrophils and macrophages). Phagocytosis is the process by which these cells engulf and digest pathogens. After processing, antigen-presenting cells display processed antigens on their surface using MHC molecules. CD4 T cells recognize these antigens and become activated. Activated T cells differentiate into plasma cells (which produce antibodies) and memory cells (which provide long-term immunological memory). Adaptive immunity includes B cells, T cells, complement system, and antigen-presenting cells. T cells mature in the thymus and are essential for cell-mediated immunity. Memory cells 'remember' specific antigens and provide long-term protection against future infections.

Innate immunity includes epithelial barriers, phagocytes (macrophages, neutrophils, mast cells), dendritic cells (bridge to adaptive immunity), complement proteins, and NK cells. Adaptive immunity involves B lymphocytes differentiating into antibody-producing plasma cells and T lymphocytes. Innate immunity recognizes pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) with limited diversity. Adaptive immunity recognizes specific antigens with high diversity through genetic recombination. Both systems have tolerance mechanisms: innate uses epithelial barriers and antimicrobial molecules, while adaptive uses antibodies for epithelial protection.

Innate immunity includes physical barriers (epithelium, skin), cellular components (neutrophils, macrophages, dendritic cells, NK cells), and soluble factors (complement, CRP). Adaptive immunity involves B cells (humoral) and T cells (cellular). B cells differentiate into plasma cells producing antibodies. T cells include helper T cells and cytotoxic T cells. Both cell types require activation through specific antigen recognition.

The SARS-CoV-2 virus has a complex structure consisting of several key components: (1) Spike glycoprotein (protein paku) - the pink-colored protein that enables the virus to attach to host cells, (2) Hemagglutinin esterase - the blue-colored protein, (3) Envelope protein - the red-colored protein surrounding the virus, (4) Nucleocapsid - the inner structure containing the genetic material, and (5) RNA genome - the genetic material of the virus. The spike glycoprotein is particularly critical as it is responsible for binding to host cell receptors.

The spike (S) protein allows the virus to attach to host cell membranes and contains a receptor binding domain that recognizes the angiotensin-converting enzyme receptor 2 (ACE2). This receptor is expressed in the lungs, heart, kidneys, and intestines. The spike protein binds to ACE2 with at least the same affinity as the SARS virus and potentially up to 20 times greater affinity, explaining why SARS-CoV-2 spreads more easily. The spike protein consists of two functional subunits: S1 binds to the host cell receptor, while S2 mediates fusion of the viral and cellular membranes. Due to its critical role in binding and cellular entry, the spike protein is a primary target for vaccine and treatment development.

The spike protein is the primary mechanism by which coronaviruses infect human cells. Named for their crown-like appearance, these spike proteins protrude from the viral envelope and bind to host cell receptors. The spike protein consists of three identical protomers that form a heavily glycosylated structure, with glycosylation providing immune protection. The receptor binding domain (RBD) exists in two conformations: a stable 'down' state and a higher-energy 'up' state. When the virus binds to angiotensin-converting enzyme 2 (ACE2) on host cells, the RBD shifts to the up conformation, enabling membrane fusion and viral entry. This structural understanding enables vaccine development through peptide-based immunization strategies.

The spike protein of the SARS-CoV-2 coronavirus is a trimeric glycoprotein composed of three identical protein chains that form a distinctive wedge-shaped structure; it consists of an outer binding domain that attaches to human cell surfaces and a central transmembrane domain containing four alpha-helices with positively charged amino acids (arginine and lysine) that help overcome the Coulomb barrier to penetrate cell membranes, enabling viral entry through membrane fusion.

The SARS-CoV-2 virus has a distinctive structure featuring prominent spike proteins (proteína S) on its surface. These spike proteins are critical for two main reasons: first, they enable the virus to infect human cells by binding to cellular receptors, particularly in the respiratory epithelium; second, they are the primary target for vaccine development and immunotherapy approaches, as antibodies must recognize and neutralize these proteins to prevent viral infection. The virus is an RNA virus with a large genome, and the spike protein is expressed as a trimer of three identical subunits.

Vaccines introduce the immune system to a weakened or inactivated version of a pathogen, allowing it to learn to recognize and fight the actual disease. This prepares the immune system so that if the real disease occurs, the body can respond quickly and effectively, often preventing symptoms entirely.

Vaccines work like military training exercises. When a vaccine is administered, it contains weakened or dead pathogens. The immune system (WBCs) attacks these weakened pathogens, learning how to recognize and fight them. This creates memory cells that remember the pathogen. When the actual pathogen enters later, the immune system can quickly recognize and destroy it before it causes disease.

Vaccination trains the immune system to recognize and fight specific pathogens without causing disease. The vaccine contains: (1) Inactivated or weakened pathogens, (2) Pathogen components, or (3) Genetic material that triggers an immune response. The immune system produces memory cells that provide long-term protection against future infections.

Vaccination introduces a weakened or inactivated form of a pathogen into the body, training the immune system to recognize and fight the actual pathogen. The immune system learns to produce antibodies against the pathogen without causing the full disease. This prepares the body for potential future exposure to the real pathogen.

Vaccination trains the immune system by exposing it to weakened or killed pathogens. The immune system learns to recognize and destroy the pathogen without causing disease. This provides long-term immunity, as seen with smallpox eradication.